<DOC>
	<DOC>NCT02003261</DOC>
	<brief_summary>This study is to examine the superiority of the combined treatments of transdiagnostic cognitive-behavior therapy (Unified Protocol; UP) and Treatment-As-Usual in comparison with the waiting-list with Treatment-As-Usual in the reduction of depressive and anxiety symptoms among depressive and anxiety disorders.</brief_summary>
	<brief_title>Japan Unified Protocol Clinical Trial for Depressive and Anxiety Disorders (JUNP Study)</brief_title>
	<detailed_description>Participants with depressive or anxiety disorders will be randomized to either Unified Protocol with Treatment-As-Usual or Wail-list with Treatment-As-Usual. Intervention period will be 20-week and the follow-up period will be 43 week from registration.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<criteria>DSMIV diagnosis of Major Depressive Disorder, Dysthymia, Depressive Disorder Not Otherwise Specified, Panic Disorder With Agoraphobia, Panic Disorder Without Agoraphobia, Agoraphobia Without History of Panic Disorder, Social Phobia(Social Anxiety Disorder), ObsessiveCompulsive Disorder, Posttraumatic Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder Not Otherwise Specified assessed by SCID. Depressive and anxiety symptoms is mild or more severe (GRIDHAMD &gt;= 8). Ages 20 years or older, and 65 years or younger at screening. Subjects who give full consent in the participation of the study. No alcohol or substance use disorder in 6 months prior to the screening assessed by SCID No current manic episode or current schizophrenia and other psychotic disorders at baseline assessed by SCID No serious suicidal ideation at baseline (GRIDHAMD Item3 severity is 3 or higher.) No lifethreatening, severe or unstable physical disorders or major cognitive deficits at baseline. Evidence of unable to participate half or more of the intervention phase. No structured psychotherapy during at baseline. Other relevant reason decided by the investigators.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>